- Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. [Journal Article]J Pathol. 2023 Feb 08 [Online ahead of print]JP
- Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally-treated and castration-resistant PCa (CRPC). In addition, close to 20% of hormonally-treated tumors recur as small cell neuroendocrine carcinoma (SCNC), composed entirely of NE cells, which may be the result of clonal expansion or lineage pl…
- Publisher Full Text (DOI)
- Prostate Cancer Associated with Minimal Change Disease: A Case Report. [Case Reports]Glomerular Dis. 2022 Jul; 2(3):145-150.GD
- Minimal change disease (MCD), a common cause of primary nephrotic syndrome that accounts for 10%-15% of all primary nephrotic syndrome cases in adults, is frequently associated with malignant lymphoma. However, studies on MCD associated with prostate cancer are scarce.
- PMC Free PDF
- Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer. [Journal Article]Cancer Med. 2023 Feb 07 [Online ahead of print]CM
- CONCLUSIONS: High SMI and low PPFA/PA could predict biochemical response to AA treatment and preferable prognosis in mCRPC patients with prior chemohormonal therapy at hormone-sensitive stage.
- Publisher Full Text (DOI)
- Prostate cancer care for American Indians and Alaska Natives. [Journal Article]Nat Rev Urol. 2023 Feb 07 [Online ahead of print]NR
- Publisher Full Text (DOI)
- CMA mediates resistance to androgen inhibitors in prostate cancer. [Journal Article]Nat Rev Urol. 2023 Feb 07 [Online ahead of print]NR
- Publisher Full Text (DOI)
- Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. [Journal Article]Nat Commun. 2023 Feb 07; 14(1):663.NC
- The treatment of low-risk primary prostate cancer entails active surveillance only, while high-risk disease requires multimodal treatment including surgery, radiation therapy, and hormonal therapy. Recurrence and development of metastatic disease remains a clinical problem, without a clear understanding of what drives immune escape and tumor progression. Here, we comprehensively describe the tumo…
- Publisher Full Text (DOI)
- HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop. [Journal Article]Cell Death Discov. 2023 Feb 07; 9(1):48.CD
- Although dysregulated HMMR is linked to prostate cancer (PCa) prognosis, the precise mechanisms remain unclear. Here, we sought to elucidate the role of HMMR in PCa progression as well as underlying mechanism. Herein, we found that upregulation of HMMR frequently observed in PCa samples and was associated with poor prognosis. Additionally, HMMR significantly promoted PCa proliferation and metasta…
- Publisher Full Text (DOI)
- RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on CTNNB1 mRNA. [Journal Article]Cell Death Dis. 2023 Feb 07; 14(2):91.CD
- Bone metastasis is the most happened metastatic event in prostate cancer (PCa) and needs a large effort in treatment. When PCa metastasizes to the bone, the new microenvironment can induce the epigenome reprogramming and stemness remodeling of cancer cells, thereby increasing the adaptability of cancer cells to the bone microenvironment, and this even leads to the occurrence of secondary tumor me…
- Publisher Full Text (DOI)
- Patients' Individualized Care Perceptions and Health Literacy Using an Interactive App During Breast and Prostate Cancer Treatment: Two Parallel Randomized Controlled Trials. [Journal Article]Comput Inform Nurs. 2023 Feb 03 [Online ahead of print]CI
- The use of symptom management mobile apps can reduce patients' symptom burden during cancer treatment, but the evidence is lacking about their effect on care. Moreover, if patients' health literacy can be improved, it needs to be more rigorously tested. This study aimed to evaluate patients' perceptions of individualized care and health literacy using an interactive app in two randomized trials. …
- Publisher Full Text (DOI)
- Macrophages promote anti-androgen resistance in prostate cancer bone disease. [Journal Article]J Exp Med. 2023 Apr 03; 220(4)JE
- Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of the metastatic microenvironment to ADT resistance remains largely unknown. The current study identified that the macrophage is the major microenvironmental component o…
- Publisher Full Text (DOI)
- Impact of previous depression on the risk of suicide among prostate cancer patients. [Journal Article]Acta Oncol. 2023 Feb 07 [Online ahead of print]AO
- CONCLUSIONS: The absolute risk of suicide is low following a prostate cancer diagnosis. Time since diagnosis and a history of depression was associated with the highest risk of suicide. Healthcare professionals should be aware of an increased risk of suicide among men with previous depression, especially in the immediate aftermath of the diagnosis.
- Publisher Full Text (DOI)
- DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations. [Journal Article]Cancer Res. 2023 Feb 07 [Online ahead of print]CR
- Metastases from primary prostate cancers to rare locations, such as the brain, are becoming more common due to longer life expectancy resulting from improved treatments. Epigenetic dysregulation is a feature of primary prostate cancer, and distinct DNA methylation profiles have been shown to be associated with the mutually exclusive SPOP mutant or TMPRSS2-ERG fusion genetic backgrounds. Using a c…
- Publisher Full Text (DOI)
- Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England. [Journal Article]J Med Econ. 2023 Jan-Dec; 26(1):208-218.JM
- CONCLUSIONS: Our holistic model suggests that switching/transitioning men from monthly or 3- monthly GnRHa therapy to a 6-monthly formulation can reduce NHS cost and capacity pressures and the societal and environmental costs associated with prostate cancer care.
- Publisher Full Text (DOI)
- The Evidence for Using Artificial Intelligence to Enhance Prostate Cancer MR Imaging. [Review]Curr Oncol Rep. 2023 Feb 07 [Online ahead of print]CO
- The purpose of this review is to summarize the current status of artificial intelligence applied to prostate cancer MR imaging.
- Publisher Full Text (DOI)
- Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy. [Review]Med Mol Morphol. 2023 Feb 07 [Online ahead of print]MM
- In this review, we discuss the possibility of the vitamin D metabolizing enzyme CYP24A1 being a therapeutic target for various tumors including breast, colorectal and prostate tumors. Given the pleiotropic cellular activity of vitamin D, its deficiency impairs its physiological function in target cells and results in various pathologies including cancer. In addition, accumulated data have shown t…
- Publisher Full Text (DOI)
- Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. [Journal Article]Eur Radiol. 2023 Feb 07 [Online ahead of print]ER
- Serial MRI is an essential assessment tool in prostate cancer (PCa) patients enrolled on active surveillance (AS). However, it has only moderate sensitivity for predicting histopathological tumour progression at follow-up, which is in part due to the subjective nature of its clinical reporting and variation among centres and readers. In this study, we used a long short-term memory (LSTM) recurren…
- Publisher Full Text (DOI)
- Impact of 3D printed models on quantitative surgical outcomes for patients undergoing robotic-assisted radical prostatectomy: a cohort study. [Journal Article]Abdom Radiol (NY). 2023 Feb 07 [Online ahead of print]AR
- CONCLUSIONS: 3D printed prostate cancer models can positively impact quantitative patient outcomes such as PSMs, operative times, and blood loss in patients undergoing RARP.
- Publisher Full Text (DOI)
- Antibody Immobilization on Sulfated Cellulose Nanocrystals. [Journal Article]Biomacromolecules. 2023 Feb 07 [Online ahead of print]B
- Exploiting cellulose nanocrystals' high aspect ratio and tailorable surface for immunological biosensors has been hindered by the relatively limited research on using commonly available sulfated cellulose nanocrystals (CNCs) for antibody immobilization and by the low hydrolytic stability of dried assemblies produced from sulfated CNCs. Herein, we report a reaction scheme that enables both hydroly…
- Publisher Full Text (DOI)
- Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan. [Journal Article]Medicine (Baltimore). 2023 Feb 03; 102(5):e32671.M
- While radium (Ra)-223 is among the multiple, known life-prolonging treatments in bone-predominant metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequencing has not been determined, particularly in the Asia-Pacific context. Hence, we aimed to compare treatment outcomes of docetaxel-naïve and post-docetaxel mCRPC patients undergoing Ra-223 therapy in Taiwan. Using a sing…
- Publisher Full Text (DOI)
- Research Progress on Gene Synthesis and Anticancer and Lipid-lowering Mechanism of Monacolin K. [Journal Article]Anticancer Agents Med Chem. 2023 Feb 07 [Online ahead of print]AA
- Monacolin K (MK), also known as lovastatin (LOV), is a secondary metabolite synthesized by Monascus in the later stage of fermentation and is the main component of functional red yeast rice (RYR). The structure of MK is similar to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), and it can competitively bind to 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), thus reducing the level of bl…
- Publisher Full Text (DOI)
- 4-nerolidylcatechol (4-NC) and Docetaxel Synergize in Controlling Androgen-independent Prostate Cancer Cells. [Journal Article]Curr Top Med Chem. 2023 Feb 07 [Online ahead of print]CT
- CONCLUSIONS: Collectively, these data demonstrated, for the first time, that the combination of 4-NC with reduced doses of DOC could be especially valuable in the suppression of oncogenic mechanisms of androgen-independent PCa cells.
- Publisher Full Text (DOI)
- Primary care physician use of patient race and polygenic risk scores in medical decision-making. [Journal Article]Genet Med. 2023 Feb 04 [Online ahead of print]GM
- CONCLUSIONS: Despite advances in precision risk stratification, physicians will likely continue to use patient race implicitly or explicitly in medical decision-making.
- Publisher Full Text (DOI)
- Role, race, and place: Prostate cancer disparities in Patients' and Partners' health outcomes and psychosocial factors. [Journal Article]Cancer Med. 2023 Feb 07 [Online ahead of print]CM
- CONCLUSIONS: Our findings underscore the need to consider social determinants of health at multiple levels when investigating PCa disparities. Considering neighborhood-level socioeconomic factors, in addition to race and role, improves our understanding of the PCa disparities in QOL, symptoms, and psychosocial factors among patients and partners. Targeted multilevel supportive care interventions should tailor to the needs of racially diverse PCa patients and partners residing in deprived neighborhoods are needed.
- Publisher Full Text (DOI)
- Deepfake Histologic Images for Enhancing Digital Pathology. [Journal Article]Lab Invest. 2023 Jan; 103(1):100006.LI
- A pathologist's optical microscopic examination of thinly cut, stained tissue on glass slides prepared from a formalin-fixed paraffin-embedded tissue blocks is the gold standard for tissue diagnostics. In addition, the diagnostic abilities and expertise of pathologists is dependent on their direct experience with common and rarer variant morphologies. Recently, deep learning approaches have been …
- Publisher Full Text (DOI)
- Glutathione-S-Transferase p1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis. [Review]Int J Endocrinol. 2023; 2023:7279243.IJ
- CONCLUSIONS: The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.
- PMC Free PDF
- CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity. [Journal Article]Heliyon. 2023 Jan; 9(1):e13044.H
- Metastatic progression and tumor evolution complicates the clinical management of cancer patients. Circulating tumor cell (CTC) characterization is a growing discipline that aims to elucidate tumor metastasis and evolution processes. CTCs offer the clinical potential to monitor cancer patients for therapy response, disease relapse, and screen 'at risk' groups for the onset of malignancy. However,…
- PMC Free PDF
- Osteolytic lesions: Multiple myeloma or prostate cancer? [Case Reports]Radiol Case Rep. 2023 Apr; 18(4):1485-1489.RC
- Multiple myeloma is a cancer which is characterized by proliferation of malignant B-cells and plasma cell infiltration of bone marrow. Lytic lesions are one of its hallmarks, on radiological assessment. We report 2 cases who presented within 1 year to our hospital with bony lytic lesions on CT scan. They were investigated for multiple myeloma; however, there were no further features to suggest th…
- PMC Free PDF
- Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. [Journal Article]Eur Urol Focus. 2023 Feb 04 [Online ahead of print]EU
- CONCLUSIONS: The adoption of TP-TBx compared with TR-TBx may reduce the risk of upgrading and improve the concordance of biopsy grade with the final pathology. The TP approach decreases the odds of CRI with improved patient selection for the correct active treatment.
- Publisher Full Text (DOI)
- Perceptions and experiences of prostate cancer patients in a public tertiary hospital in urban South Africa. [Journal Article]Ethn Health. 2023 Feb 06 [Online ahead of print]EH
- ABSTRACTProstate cancer is among the most prevalent forms of cancer worldwide and is reported to have the highest incidence, mortality, and 5-year prevalence rate of all cancers among men living in Africa. Despite this widespread burden in the African continent, little is known about the perspectives and experience of prostate cancer among African men. To further understand experiences among pati…
- Publisher Full Text (DOI)
- Deciphering the modulatory role of apigenin targeting oncogenic pathways in human cancers. [Review]Chem Biol Drug Des. 2023 Feb 06 [Online ahead of print]CB
- Cancer is a complicated malignancy controlled by numerous intrinsic and extrinsic pathways. There has been a significant increase in interest in recent years in the elucidation of cancer treatments based on natural extracts that have fewer side effects. Numerous natural product-derived chemicals have been investigated for their anticancer effects in the search for an efficient chemotherapeutic me…
- Publisher Full Text (DOI)